CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Randomized, Phase II Study of Selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer.
Authors
Eric Chen
Stephanie De Luca
+12Â more
Neesha Dhani
Mark K Doherty
David Hedley
Raymond Jang
Jennifer J Knox
Mairead G Mcnamara
Grainne M O'Kane
Theresa Pedutem
Hao-Wen Sim
Vincent C Tam
Patricia Tang
Lisa Wang
Publication date
1 January 2032
Publisher
Abstract
Abstract is not available.
Similar works
Full text
Available Versions
The University of Manchester - Institutional Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.atira.dk:publications...
Last time updated on 22/07/2022